Clinical Trials Logo

Hepato Cellular Carcinoma clinical trials

View clinical trials related to Hepato Cellular Carcinoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT03706157 Completed - Clinical trials for Hepato Cellular Carcinoma

Kinectics of Distribution of Doxorubicin-Lipiodol Emulsion in c-TACE

CineDoxo
Start date: November 26, 2018
Phase: Phase 4
Study type: Interventional

Conventional transarterial chemoembolization with Doxorubicin (c-TACE) is the gold standard treatment for Hepato Cellular Carcinoma (HCC) stage B (BCLC) / stages A and B (Child-Pugh). Clinical recommendations for cTACE indicate that the doxorubicin solution may be reconstituted in either aqueous solution or iso-osmolar ionic iodinated contrast media. There is no consensus on which solvent should be used. Hence, the clinical evaluation of Lipiodol cTACE would benefit from a standardization in the reconstitution of the drug. In this study, the comparison of the kinetics of distribution of the drug within the tumor micro-environment is expected to allow for comparison of drug solvents. This pilot study aims at evaluating the kinetics of distribution of the drug within the tumor micro-environment, for the two main solvents used in reconstituting the drug, namely normal saline and contrast media. The kinetics of distribution in the tumor will be evaluated primarily through regular biopsy sampling, and secondary with confocal laser endomicroscopy.